EMVO Names Service Providers for FMD Project

June 25, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-07-01-2015, Volume 11, Issue 7

The European Medicines Verification Organization has signed agreements with service providers to establish blueprint systems in compliance with the Falsified Medicines Directive.

The European Medicines Verification Organization (EMVO) announced that it has finalized its contract negotiations with three partners-Aegate Holdings Limited, Arvato Systems GmbH, and Solidsoft Reply. These companies are listed as the preferred providers to implement the repositories system in compliance with the Falsified Medicines Directive.

The EMVO is a non-profit organization established in February 2015 by five European stakeholder associations-the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic and Biosimilar medicines Association (EGA), the Pharmaceutical Group of the European Union (PGEU), the European Association of Pharmaceutical Full-line Wholesalers (GIRP), and the European Association of Euro-Pharmaceutical Companies (EAEPC). Representing stakeholders united in securing the legal supply chain from falsified medicines, it is leading the initiative to create a repositories system that will allow the verification for authentication of medicines in Europe.

The EMVO has designed a blueprint model that ensures a practical and cost-effective implementation of these repositories to minimize the burden of national stakeholder organization or NMVOs that eventually will be responsible for the establishment and management of the systems. It includes a support plan or implementation package and a short list of preferred service providers. NMVOs will have the opportunity to select a service provider best suited to establish a repository system in their Member State.

Through the engagement of the whole pharmaceutical supply chain and with the support of our new partners, the EMVO has taken a major step to secure the legitimate supply chain and to prevent falsified medicines from reaching patients. “The agreement with our new partners brings us a step forward in the fight against falsified medicines,” said EMVO director general ad-interim Andreas Walter in a press statement. “We would like to encourage national stakeholders to take the example of EMVO, establish NMVOs, and sign up with one of our selected service providers.”

Source: EMVO